Anavex Life Sciences Corp.

NASDAQ:AVXL

Biotechnology

Healthcare
$0.72 -1.67%

-$0.04 today

Market cap
$66.69M
Beta
1.12
P/E (TTM)
-5.9
EPS (TTM)
-$0.45
52W Low $2.41High $13.99

Volume 1.06M

Average 1.39M

AVXL Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

Anavex Life Sciences Corp.NASDAQ: AVXL

Financing Cash Flow · Q1 FY2026 · quarter ended Dec 2025

Financing cash flow growth accelerates

Q1 FY2026 financing cash flow of $36.32M rose 5030.4% year over year, ahead of the +256.9% change in trailing-twelve-month financing cash flow. Sequentially, it rose 262.6% from the prior quarter. Over 3 fiscal years it compounded at -23.8% a year.

Context

  • Financing cash flow increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +5030.4% holds above the trailing-twelve-month pace of +256.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterDec 2025
$36.32M+262.6% QoQ
Last fiscal yearSep 2025
$9.43M-21.2% YoY
LTMDec 2025
$45.05M+256.9% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+5030.4%——
1 year-21.2%——
3-year CAGR-23.8%——
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
9.43M USD
Year-over-year change
-21.2%
4-year CAGR
-50.2%

Financing Cash Flow vs competitors

How AVXL compares with its peers on the latest reported figures

  • Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +256.9% is the 4th highest of 10, against a peer median of +40.9%.
  • Over three fiscal years its annual growth of -23.8% compares with a peer median of +33.6%.
AVXL Competitors
Financing Cash Flow for AVXL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ERASErasca, Inc.LTM Sep 2026$845.81M USD+63879.3%-77.6%—
CTMXCytomX Therapeutics, Inc.LTM Mar 2026$344.93M USD+4594.2%+454.4%970.5%
MBXMBX Biosciences, Inc. Common StockLTM Sep 2026$189.81M USD+0.4%+60.3%—
RGNXREGENXBIO Inc.LTM Mar 2026$108.93M USD+421.9%—124.0%
MLTXMoonLake ImmunotherapeuticsLTM Mar 2026$103.52M USD+40.9%+6.8%—
ARVNArvinas, Inc.LTM Mar 2026$91.4M USD-1574.2%—102.2%
ABSIAbsci CorporationLTM Mar 2026$70.71M USD+60.2%+172.5%3851.4%
AVXLAnavex Life Sciences Corp.LTM Dec 2025$45.05M USD+256.9%-23.8%—
VALNValneva SELTM Mar 2026€33.89M EUR+4.1%—21.7%
MGTXMeiraGTx Holdings plcLTM Mar 2026$446K USD-99.2%-49.5%0.6%
Peer median (excluding AVXL) —+40.9%+33.6%113.1%

Competitors are the stored peer set for AVXL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Sep 2021
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Net Income(37.91M)(47.98M)(47.51M)(43M)(46.38M)
Depreciation & Amortization00000
Deferred Income Tax00000
Stock-Based Compensation8.23M18.38M16.37M9.44M11.55M
Change in Working Capital(706K)5.36M2.51M2.75M(4.22M)
Accounts Receivables(4.29M)5.94M484K260K1.64M
Inventory00000
Accounts Payables751K(914K)497K5.31M(5.38M)
Other Working Capital2.83M331K1.52M(2.81M)(478K)
Other Non-Cash Items00845K00
Operating Cash Flow(30.38M)(24.24M)(27.79M)(30.81M)(39.04M)
Capital Expenditures00000
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow00000
Debt Repayment00000
Common Stock Issued153.22M22M29.65M11.98M12.14M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities24K(707K)29.65M11.98M(2.71M)
Financing Cash Flow153.24M21.29M29.65M11.98M9.43M
Effect of Forex Changes00000
Net Change in Cash122.86M(2.95M)1.87M(18.84M)(29.61M)
Free Cash Flow(30.38M)(24.24M)(27.79M)(30.81M)(39.04M)

Anavex Life Sciences Corp.

NASDAQ:AVXL

Intrinsic Alpha fair value

Locked

Current Price

$0.72

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.